Prostate cancer treatment can be tricky to get right: Over-treatment can bring unnecessary side-effects, while under-treatment risks letting the disease spread. This is why medical software company Artera uses AI, combined with a dataset of patient records and biopsy images, to create a targeted treatment plan. “When you’re treating cancer, you’re trying to predict if their future is better on one therapy or another, and that’s really difficult,” says Andre Esteva, Artera’s founder and CEO. “It turns out, AI is spectacular at it.” So much so that the National Comprehensive Cancer Network now recommends Artera’s Multimodal Artificial Intelligence platform as the official standard of care for prostate cancer.
Disclosure: Investors in ArteraAI include TIME co-chair and owner Marc Benioff.
More Must-Reads from TIME
- How Donald Trump Won
- The Best Inventions of 2024
- Why Sleep Is the Key to Living Longer
- How to Break 8 Toxic Communication Habits
- Nicola Coughlan Bet on Herself—And Won
- What It’s Like to Have Long COVID As a Kid
- 22 Essential Works of Indigenous Cinema
- Meet TIME's Newest Class of Next Generation Leaders
Contact us at letters@time.com